Misonix Incorporated Enhances Its Digital Presence With The Unveiling Of Its New Bonescalpel™ App

FARMINGDALE, N.Y., July 24, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announces the launch of its BoneScalpel app for iPad mobile devices.

The new iPad app was designed to educate users on the extensive benefits of the ultrasonic BoneScalpel for spine surgery. Users can explore the science behind the BoneScalpel with 2D animation of the innovative ultrasound technology, witness the precise cutting and shaving abilities in the video portfolio, and observe the surgical technique used for cutting bone with an interactive 3D spine model. The app also contains extensive material on BoneScalpel’s clinical and economic benefits, key publications and endorsements from distinguished surgeons who have made BoneScalpel a standard of care in their practice.

As Dr. Eric J. Woodard, MD, Chief of Neurosurgery at New England Baptist Hospital explains: “While the use of the BoneScalpel has become standard practice at our institution for performing spinal procedures, for those surgeons without firsthand experience with the device, they need to understand the significant differences and benefits the device affords them. Given the unique ultrasonic mechanism by which the BoneScalpel actually cuts bone, and the safety and efficiency that it imparts to the overall surgical procedure, one of the best ways to illustrate these benefits is through tools like this new app. Having been involved in medical education throughout my career it was an absolute pleasure to contribute to this project by translating one of our surgical techniques into a teaching model with interactive 3D viewing. With this app, surgeons now will better appreciate how the BoneScalpel works and the benefits it will bring to their patients and operating rooms.”

“This new iPad app is a significant advancement in our commitment to develop new tools to better communicate with our rapidly expanding global customer base and international stakeholders. We will continue to expand this digital platform through regular updates to include new information, surgical videos, product offerings and functionality, which will be available in the Apple iTunes store. Surgeons around the world now have direct access to the most up-to-date BoneScalpel technical information and they also have the ability to schedule a surgical evaluation directly through the app,” stated Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.